Therapeutic strategies to overcome ALK resistance in cancer /

"Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops....

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Friboulet, Luc (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London, United Kingdom : Academic Press, an imprint of Elsevier, [2021]
Colección:Cancer sensitizing agents for chemotherapy ; v. 13.
Temas:
Lungs > Cancer > Treatment.
Anaplastic Lymphoma Kinase > antagonists & inhibitors
Lung Neoplasms > drug therapy
Antineoplastic Agents > pharmacology
Protein Kinase Inhibitors > therapeutic use
Poumons > Cancer > Traitement.
Lungs > Cancer > Treatment
Internet Resources.
Index not Present.
Acceso en línea:Texto completo
Descripción
Sumario:"Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field"--Publisher's description.
Descripción Física:1 online resource (xix, 195 pages) : illustrations (some color), portraits (some color).
Bibliografía:Includes bibliographical references and index.
ISBN:9780128217795
0128217790

Ejemplares similares